Oncology Market Access at Risk: Is a Carrot for MDs a Stick for Pharma Companies
When Considering a Merger, Ask Why
Building the Fundamentals: Why Bold Sales Incentive Schemes Need Efficient Administration
Why Medtech's Commercial Models Must Adapt to Local Needs
Allergan Case Study: A Smart Response to Growth
Biopharma Companies Identify Biggest Challenges and Opportunities in Targeting and Activity Planning
The Promise of Immunotherapy and Early Successes
Our immune systems may be one of the most powerful resources that we have in the fight against cancer. With all of the mounting evidence of immunotherapy used to treat melanoma, lung cancer and bladder cancer, immunotherapy as a treatment option is here to stay. But as highlighted on many occasions and again at ASCO [1], immunotherapy doesn’t always work.
Read MoreTopics: Nisha Gilra, ASCO, immunotherapy, ASCO2016
The Promise of Immunotherapy and Early Successes
Our immune systems may be one of the most powerful resources that we have in the fight against cancer. With all of the mounting evidence of immunotherapy used to treat melanoma, lung cancer and bladder cancer, immunotherapy as a treatment option is here to stay. But as highlighted on many occasions and again at ASCO [1], immunotherapy doesn’t always work.
View All ZS Offices
